Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998406048> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W1998406048 endingPage "468" @default.
- W1998406048 startingPage "464" @default.
- W1998406048 abstract "Objective. This was a phase II study of perillyl alcohol in the treatment of advanced ovarian cancer. The primary endpoint was to evaluate the 6-month progression-free rate of perillyl alcohol as compared with historic controls. Secondary objectives were to evaluate the objective response rate, time to progression and survival, dropout rate, and number of cycles administered; define the qualitative nature of acute and chronic toxicities; and evaluate the effect of perillyl alcohol on triglycerides and total, HDL, and LDL cholesterol levels. Methods. Women who had received prior platinum-based therapy and had residual or recurrent disease were eligible. Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m2. This was repeated until disease progression or unacceptable toxicity was experienced. Results. The 6-month progression-free rate was 17%. None of the patients achieved a complete or partial response. The median progression-free survival was 1.7 months. The median overall survival was 9.1 months. Compliance was greater than 90% but gastrointestinal toxicity (grade 1–2 nausea, satiety, eructation in 70%) and fatigue (grade 1–2 in 40%) were common and limited the ability to escalate the dose from 1200 to 1500 mg/m2. Conclusion. Perillyl alcohol administered at this dose and formulation did not exhibit signs of extending the time-to-progression in patients with advanced ovarian carcinoma." @default.
- W1998406048 created "2016-06-24" @default.
- W1998406048 creator A5005756097 @default.
- W1998406048 creator A5016030632 @default.
- W1998406048 creator A5024528272 @default.
- W1998406048 creator A5029363412 @default.
- W1998406048 creator A5052993364 @default.
- W1998406048 creator A5071579916 @default.
- W1998406048 creator A5075153337 @default.
- W1998406048 date "2002-06-01" @default.
- W1998406048 modified "2023-10-17" @default.
- W1998406048 title "A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96" @default.
- W1998406048 cites W1522954291 @default.
- W1998406048 cites W1831044128 @default.
- W1998406048 cites W2077306345 @default.
- W1998406048 cites W2141258764 @default.
- W1998406048 cites W2159428951 @default.
- W1998406048 cites W2321791130 @default.
- W1998406048 cites W4293241248 @default.
- W1998406048 doi "https://doi.org/10.1006/gyno.2002.6647" @default.
- W1998406048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12051875" @default.
- W1998406048 hasPublicationYear "2002" @default.
- W1998406048 type Work @default.
- W1998406048 sameAs 1998406048 @default.
- W1998406048 citedByCount "61" @default.
- W1998406048 countsByYear W19984060482012 @default.
- W1998406048 countsByYear W19984060482014 @default.
- W1998406048 countsByYear W19984060482015 @default.
- W1998406048 countsByYear W19984060482016 @default.
- W1998406048 countsByYear W19984060482017 @default.
- W1998406048 countsByYear W19984060482018 @default.
- W1998406048 countsByYear W19984060482019 @default.
- W1998406048 countsByYear W19984060482020 @default.
- W1998406048 countsByYear W19984060482021 @default.
- W1998406048 countsByYear W19984060482023 @default.
- W1998406048 crossrefType "journal-article" @default.
- W1998406048 hasAuthorship W1998406048A5005756097 @default.
- W1998406048 hasAuthorship W1998406048A5016030632 @default.
- W1998406048 hasAuthorship W1998406048A5024528272 @default.
- W1998406048 hasAuthorship W1998406048A5029363412 @default.
- W1998406048 hasAuthorship W1998406048A5052993364 @default.
- W1998406048 hasAuthorship W1998406048A5071579916 @default.
- W1998406048 hasAuthorship W1998406048A5075153337 @default.
- W1998406048 hasConcept C126322002 @default.
- W1998406048 hasConcept C141071460 @default.
- W1998406048 hasConcept C143998085 @default.
- W1998406048 hasConcept C168563851 @default.
- W1998406048 hasConcept C203092338 @default.
- W1998406048 hasConcept C2776694085 @default.
- W1998406048 hasConcept C2780580376 @default.
- W1998406048 hasConcept C2780739268 @default.
- W1998406048 hasConcept C29730261 @default.
- W1998406048 hasConcept C71924100 @default.
- W1998406048 hasConcept C90924648 @default.
- W1998406048 hasConceptScore W1998406048C126322002 @default.
- W1998406048 hasConceptScore W1998406048C141071460 @default.
- W1998406048 hasConceptScore W1998406048C143998085 @default.
- W1998406048 hasConceptScore W1998406048C168563851 @default.
- W1998406048 hasConceptScore W1998406048C203092338 @default.
- W1998406048 hasConceptScore W1998406048C2776694085 @default.
- W1998406048 hasConceptScore W1998406048C2780580376 @default.
- W1998406048 hasConceptScore W1998406048C2780739268 @default.
- W1998406048 hasConceptScore W1998406048C29730261 @default.
- W1998406048 hasConceptScore W1998406048C71924100 @default.
- W1998406048 hasConceptScore W1998406048C90924648 @default.
- W1998406048 hasIssue "3" @default.
- W1998406048 hasLocation W19984060481 @default.
- W1998406048 hasLocation W19984060482 @default.
- W1998406048 hasOpenAccess W1998406048 @default.
- W1998406048 hasPrimaryLocation W19984060481 @default.
- W1998406048 hasRelatedWork W2081790265 @default.
- W1998406048 hasRelatedWork W2139647583 @default.
- W1998406048 hasRelatedWork W2183237771 @default.
- W1998406048 hasRelatedWork W2540335153 @default.
- W1998406048 hasRelatedWork W2589963932 @default.
- W1998406048 hasRelatedWork W2789668336 @default.
- W1998406048 hasRelatedWork W2891273047 @default.
- W1998406048 hasRelatedWork W4231598961 @default.
- W1998406048 hasRelatedWork W4285492859 @default.
- W1998406048 hasRelatedWork W4308189788 @default.
- W1998406048 hasVolume "85" @default.
- W1998406048 isParatext "false" @default.
- W1998406048 isRetracted "false" @default.
- W1998406048 magId "1998406048" @default.
- W1998406048 workType "article" @default.